Tree species composition and diversity gradients in white-water forests across the Amazon Basin von Wittmann, Florian, Schöngart, Jochen, Montero, Juan Carlos, Motzer, Thomas, Junk, Wolfgang J., Piedade, Maria T. F., Queiroz, Helder L., Worbes, Martin

Volltext

Micrometeorological aspects of a tropical mountain forest von Motzer, Thomas

Volltext

Stomatal conductance, transpiration and sap flow of tropical montane rain forest trees in the southern Ecuadorian Andes von Motzer, T, Munz, N, Kuppers, M, Schmitt, D, Anhuf, D

Volltext

ORIGINAL ARTICLE: Tree species composition and diversity gradients in white-water forests across the Amazon Basin von Wittmann, Florian, Schoengart, Jochen, Montero, Juan Carlos, Motzer, Thomas, Junk, Wolfgang J, Piedade, Maria TF, Queiroz, Helder L, Worbes, Martin

Volltext

Water Budget of the Surumoni Crane Site (Venezuela) von Anhuf, Dieter, Motzer, Thomas, Rollenbeck, Rütger, Schröder, Birgit, Szarzynski, Jörg

Volltext

Fill level sensor or pressure sensor comprising anti-adhesive layer von JACOB JOERN,MOTZER JUERGEN,DECK THOMAS,FEHRENBACHJOSEF

Volltext bestellen

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial von Choueiri, Toni K, Dr, Escudier, Bernard, MD, Powles, Thomas, Prof, Tannir, Nizar M, Prof, Mainwaring, Paul N, MD, Rini, Brian I, Prof, Hammers, Hans J, MD, Donskov, Frede, MD, Roth, Bruce J, Prof, Peltola, Katriina, MD, Lee, Jae Lyun, Prof, Heng, Daniel Y C, MD, Schmidinger, Manuela, Prof, Agarwal, Neeraj, MD, Sternberg, Cora N, Prof, McDermott, David F, MD, Aftab, Dana T, PhD, Hessel, Colin, MS, Scheffold, Christian, MD, Schwab, Gisela, MD, Hutson, Thomas E, Prof, Pal, Sumanta, MD, Motzer, Robert J, Prof

Volltext

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade von Motzer, Robert J., Banchereau, Romain, Hamidi, Habib, Powles, Thomas, McDermott, David, Atkins, Michael B., Escudier, Bernard, Liu, Li-Fen, Leng, Ning, Abbas, Alexander R., Fan, Jinzhen, Koeppen, Hartmut, Lin, Jennifer, Carroll, Susheela, Hashimoto, Kenji, Mariathasan, Sanjeev, Green, Marjorie, Tayama, Darren, Hegde, Priti S., Schiff, Christina, Huseni, Mahrukh A., Rini, Brian

Volltext

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial von Motzer, Robert J, Dr, Hutson, Thomas E, DO, Glen, Hilary, MD, Michaelson, M Dror, MD, Molina, Ana, MD, Eisen, Timothy, Prof, Jassem, Jacek, Prof, Zolnierek, Jakub, MD, Maroto, Jose Pablo, MD, Mellado, Begoña, MD, Melichar, Bohuslav, Prof, Tomasek, Jiri, MD, Kremer, Alton, MD, Kim, Han-Joo, PhD, Wood, Karen, PhD, Dutcus, Corina, MD, Larkin, James, FRCP

Volltext

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial von Motzer, Robert J., Robbins, Paul B., Powles, Thomas, Albiges, Laurence, Haanen, John B., Larkin, James, Mu, Xinmeng Jasmine, Ching, Keith A., Uemura, Motohide, Pal, Sumanta K., Alekseev, Boris, Gravis, Gwenaelle, Campbell, Matthew T., Penkov, Konstantin, Lee, Jae Lyun, Hariharan, Subramanian, Wang, Xiao, Zhang, Weidong, Wang, Jing, Chudnovsky, Aleksander, di Pietro, Alessandra, Donahue, Amber C., Choueiri, Toni K.

Volltext

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial von Motzer, Robert J, Dr, Escudier, Bernard, MD, Tomczak, Piotr, MD, Hutson, Thomas E, DO, Michaelson, M Dror, MD, Negrier, Sylvie, Prof, Oudard, Stephane, Prof, Gore, Martin E, Prof, Tarazi, Jamal, MD, Hariharan, Subramanian, MD, Chen, Connie, PharmD, Rosbrook, Brad, MS, Kim, Sinil, MD, Rini, Brian I, MD

Volltext

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma von Escudier, Bernard, Sharma, Padmanee, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Gurney, Howard, Donskov, Frede, Peltola, Katriina, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Zhao, Huanyu, Waxman, Ian M, Motzer, Robert J

Volltext

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial von Rini, Brian I, Dr, Escudier, Bernard, MD, Tomczak, Piotr, MD, Kaprin, Andrey, Prof, Szczylik, Cezary, MD, Hutson, Thomas E, DO, Michaelson, M Dror, MD, Gorbunova, Vera A, Prof, Gore, Martin E, Prof, Rusakov, Igor G, Prof, Negrier, Sylvie, Prof, Ou, Yen-Chuan, Prof, Castellano, Daniel, MD, Lim, Ho Yeong, Prof, Uemura, Hirotsugu, Prof, Tarazi, Jamal, MD, Cella, David, PhD, Chen, Connie, PharmD, Rosbrook, Brad, MS, Kim, Sinil, MD, Motzer, Robert J, MD

Volltext

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial von MOTZER, Robert J, NOSOV, Dmitry, KOGAN, Mikhail, ALEKSEEV, Boris Y, STERNBERG, Cora N, SZCZYLIK, Cezary, CELLA, David, IVANESCU, Cristina, KRIVOSHIK, Andrew, STRAHS, Andrew, ESTEVES, Brooke, BERKENBLIT, Anna, EISEN, Timothy, HUTSON, Thomas E, BONDARENKO, Igor, LESOVOY, Vladimir, LIPATOV, Oleg, TOMCZAK, Piotr, LYULKO, Oleksiy, ALYASOVA, Anna, HARZA, Mihai

Volltext

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma von Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J

Volltext

Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib von Motzer, Robert J, Hutson, Thomas E, McCann, Lauren, Deen, Keith, Choueiri, Toni K

Volltext

Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma von Motzer, Robert J, Hutson, Thomas E, Ren, Min, Dutcus, Corina, Larkin, James

Volltext

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial von Motzer, Robert J, Dr, Prof, Escudier, Bernard, MD, Oudard, Stéphane, Prof, Hutson, Thomas E, Prof, Porta, Camillo, MD, Bracarda, Sergio, MD, Grünwald, Viktor, Prof, Thompson, John A, Prof, Figlin, Robert A, Prof, Hollaender, Norbert, PhD, Urbanowitz, Gladys, BS, Berg, William J, MD, Kay, Andrea, MD, Lebwohl, David, MD, Ravaud, Alain, Prof

Volltext

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Tannir, Nizar M, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Choueiri, Toni K, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Neiman, Victoria, Kollmannsberger, Christian K, Salman, Pamela, Gurney, Howard, Hawkins, Robert, Ravaud, Alain, Grimm, Marc-Oliver, Bracarda, Sergio, Barrios, Carlos H, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Chen, Allen C, Mekan, Sabeen, McHenry, M. Brent, Wind-Rotolo, Megan, Doan, Justin, Sharma, Padmanee, Hammers, Hans J, Escudier, Bernard

Volltext

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma von Motzer, Robert J., Escudier, Bernard, Powles, Thomas, Scheffold, Christian, Choueiri, Toni K.

Volltext